Package Leaflet: Information for the User
Influvac injectable suspension in a pre-filled syringe
Influenza vaccine (inactivated surface antigen)
2025/2026 Campaign
Read all of this leaflet carefully before you or your child are vaccinated, because it contains important information for you and your child.
Contents of the package leaflet:
Influvac is a vaccine for adults and children from 6 months of age. This vaccine helps protect you or your child against the flu virus. The use of Influvac should be based on official recommendations.
When the Influvac vaccine is administered to a person, the immune system (the body's natural defense system) will produce its own protection (antibodies) against the disease. None of the components of the vaccine can cause the flu.
The flu is a disease that can spread quickly and is caused by different types of strains that can change every year. For this reason, you or your child may need to be vaccinated every year. The greatest risk of getting the flu occurs during the cold months, between October and March. If you or your child were not vaccinated in the fall, it is still reasonable to be vaccinated until the spring, as you or your child are at risk of getting the flu until then. Your doctor can recommend the best time to be vaccinated.
Influvac will protect you or your child against the three strains of the virus contained in the vaccine from approximately 2 to 3 weeks after injection.
The incubation period for the flu is a few days, so if you or your child are exposed to the flu virus immediately before or after being vaccinated, it is possible to develop the disease.
The vaccine will not protect you or your child against the common cold, although some of the symptoms are similar to those of the flu.
To ensure that Influvac is suitable for you or your child, it is important that you consult your doctor, pharmacist, or nurse if any of the following points apply to you or your child. If there is anything you do not understand, ask your doctor, pharmacist, or nurse to explain it to you.
Do not use Influvac
Warnings and precautions
Before vaccination, you must inform your doctor if you or your child have:
Your doctor will decide if you or your child should receive the vaccine.
If you or your child have a disease accompanied by high fever or an acute infection, vaccination should be postponed until you or your child have recovered.
After or even before injection with a needle, fainting (fainting), dizziness, or other stress-related reactions may occur. Therefore, you should inform your doctor or nurse if you experience or have experienced this type of reaction previously with an injection.
If, for any reason, you or your child have a blood test a few days after flu vaccination, please inform your doctor. This is because false-positive blood test results have been observed in some patients who have recently been vaccinated.
Like all vaccines, Influvac may not completely protect all people who are vaccinated.
Other medicines and Influvac
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor for advice before using this medication.
Inactivated influenza vaccines can be used at all stages of pregnancy.
More safety data are available for the second and third trimesters compared to the first trimester. However, data on the global use of influenza vaccines do not indicate that the vaccine can have harmful effects on pregnancy or the baby.
Influvac can be used during breastfeeding.
Your doctor, pharmacist, or nurse can decide if you should receive Influvac.
Consult your doctor, pharmacist, or nurse before taking any medication.
Driving and using machines
The influence of Influvac on the ability to drive or use machines is nil or insignificant.
Influvac contains sodium and potassium
This medication contains less than 1 mmol of sodium (23 mg) per dose, i.e., it is essentially "sodium-free".
This medication contains potassium, less than 1 mmol (39 mg) per dose, i.e., it is essentially "potassium-free".
Dosage
Adults receive a single dose of 0.5 ml.
Use in children and adolescents
Children from 6 months to 17 years of age receive a single dose of 0.5 ml.
Children under 9 years of age who have not been previously vaccinated against seasonal flu: a second dose should be administered after an interval of at least 4 weeks.
The safety and efficacy of Influvac have not been established for infants under 6 months of age.
Route(s) and/or method of administration
Your doctor or nurse will administer the recommended dose of the vaccine by intramuscular or deep subcutaneous injection.
If you have any further questions on the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medications, Influvac can cause side effects, although not everyone gets them.
Consult your doctor immediately if you or your child experience any of the following side effects; you or your child may need urgent medical attention.
Severe allergic reactions (frequency not known, occasionally occurring during general use of Influvac):
During clinical trials with Influvac and/or Influvac Tetra, the following side effects were observed. Their frequency has been estimated as:
Side effects | Adults and elderly population | Children | ||
18 years or older | 6 to 35 months | 3 to 5 years | 6 to 17 years | |
Headache | Very common* | - | - | Very common |
Somnolence | - | Very common | Very common | - |
Sweating | Common | Very common | Common | Common |
Loss of appetite | - | Very common | Very common | - |
Nausea | - | - | - | Very common |
Abdominal pain | - | - | - | Very common |
Diarrhea | - | Very common | Common | Very common |
Vomiting | - | Very common | Common | Very common |
Irritability/agitation | - | Very common | Very common | - |
Muscle pain (myalgia) | Common | - | - | Very common |
Joint pain (arthralgia) | Common | - | - | Common |
Fatigue | Very common | - | - | Very common |
Fever | Uncommon | Very common | Common | Common |
General feeling of discomfort | Common | - | - | Very common |
Chills | Common | - | - | Common |
Pain at the injection site | Very common | Very common | Very common | Very common |
Redness | Common | Very common | Very common | Very common |
Swelling | Common | Common | Very common | Very common |
Hardening (induration) | Common | Common | Very common | Very common |
Bruising (ecchymosis) | Common | Common | Common | Common |
For all age groups: Frequency not known (cannot be estimated from available data) | Skin reactions that can spread throughout the body, including itching of the skin (pruritus, urticaria), rash. | |||
Inflammation of blood vessels that can lead to skin rashes (vasculitis) and, in very rare cases, temporary kidney problems. | ||||
Localized pain in nerve endings (neuralgia), abnormalities in the perception of touch, pain, heat, and cold (paresthesia), febrile seizures, neurological disorders that can cause stiffness of the neck, confusion, numbness, pain, and weakness of the limbs, loss of balance, loss of reflexes, paralysis of all or part of the body (encephalomyelitis, neuritis, Guillain-Barré syndrome). | ||||
Temporary reduction in the number of certain types of blood particles called platelets; a low platelet count can cause excessive bruising or bleeding (transient thrombocytopenia); temporary inflammation of the glands in the neck, armpits, or groin (transient lymphadenopathy). | ||||
*Common in the elderly population (≥ 61 years) |
In all age groups, most of the reactions mentioned above usually occur within 3 days after vaccination and resolve spontaneously within 1 to 3 days after their onset. In general, the intensity of these reactions was mild.
Reporting of side effects
If you or your child experience any side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep out of sight and reach of children.
Do not use Influvac after the expiration date stated on the packaging after EXP. The expiration date is the last day of the month indicated.
Store Influvac in the refrigerator (between 2°C - 8°C). Do not freeze.
Keep the product in its original packaging to protect it from light.
Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medication at the pharmacy's SIGRE collection point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Influvac composition
The active ingredients are:
Influenza virus surface antigens (hemagglutinin and neuraminidase), of the following strains*:
(A/Victoria/4897/2022, IVR-238).......15 micrograms HA**
(A/Croatia/10136RV/2023, X-425A).......................15 micrograms HA**
(B/Austria/1359417/2021, BVR-26)…........15 micrograms HA**
per 0.5 ml dose
** hemagglutinin
This vaccine complies with the World Health Organization (WHO) recommendation (Northern Hemisphere) and with the European Union recommendation for the 2025/2026 campaign.
The other components are: potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, sodium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and water for injections.
Appearance of Influvac and container contents
Influvac is an injectable suspension presented in glass pre-filled syringes (with or without a needle), with a plunger stopper (bromobutyl rubber), containing 0.5 ml of clear and colorless liquid for injection. Each syringe is for single use.
Container with 1 or 10 syringes.
Not all formats may be marketed.
Marketing authorization holder:
Viatris Healthcare Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer responsible for the medicinal product:
Abbott Biologicals B.V.
Veerweg 12
NL - 8121 AA Olst
Netherlands
Further information on this medicinal product can be obtained from the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.
C/ General Aranaz, 86
28027 Madrid
Spain
This medicinal product is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Austria | Influvac - Tri Injektionssuspension in einer Fertigspritze, (Influenza-Impfstoff aus inaktivierten Oberflächenantigenen) |
Belgium | Influvac, suspensie voor injectie in een voorgevulde spuitGriepvaccin (oppervlakte-antigenen, geïnactiveerd) |
Bulgaria | ???????? ??????????? ????????? ? ????????????? ????????? ?????????? (B?????? ????? ????, ???????????? ???????, ???????????) |
Croatia | Influvac suspenzija za injekciju u napunjenoj štrcaljki, cjepivo protiv influence (površinski antigen), inaktivirano |
Cyprus, Malta | Influvac sub-unit, suspension for injection(influenza vaccine, surface antigen, inactivated) |
Czech Republic, Denmark, Estonia, Finland, Germany, Iceland, Norway, Poland, Portugal, Slovakia, Sweden | Influvac |
France | INFLUVAC, suspension injectable en seringue préremplie vaccin grippal inactivé à antigènes de surface |
Greece | Influvac sub-unit |
Hungary | Influvac szuszpenziós injekció eloretöltött fecskendoben |
Ireland | Influvac sub-unit, suspension for injection in pre-filled syringeInfluenza vaccine (surface antigen, inactivated) |
Italy | Influvac S |
Latvia | Influvac suspensija injekcijam pilnšlirce |
Lithuania | Influvac injekcine suspensija užpildytame švirkšte |
Luxembourg | Influvac suspension injectable en seringue préremplie Vaccin contre la grippe (antigènes de surface, inactivés) |
Netherlands | Influvac, suspensie voor injectie in voorgevulde spuit 0,5 ml |
Romania | Influvac suspensie injectabila în seringa preumpluta |
Slovenia | Influvac suspenzija za injiciranje v napolnjeni injekcijski brizgi |
Spain | Influvac suspensión inyectable en jeringa precargada |
This leaflet was last revised in:July 2025
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/
------------------------------------------------------------------------------------------------------------------------------
This information is intended for healthcare professionals only
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following administration of the vaccine.
The vaccine should be allowed to reach room temperature.
Shake before use.
Inspect visually before administration.
Do not use the vaccine if the color has changed or foreign particles are observed in the suspension.
Do not mix with other medicinal products in the same syringe.
The vaccine must not be administered directly into any blood vessel.
The recommended sites for intramuscular injection are the anterolateral aspect of the thigh (or the deltoid muscle if the muscle mass is adequate) in children from 6 to 35 months of age, or the deltoid muscle in children from 36 months of age and adults.
Traceability
To improve the traceability of biological medicinal products, the name and batch number of the administered product must be clearly recorded.
See also section 3: How to use Influvac